Desarrollo farmacéutico de la nano emulsión de crisaborol para el tratamiento de la dermatitis atópica

Abstract

Abstract: Atopic dermatitis (AD) is the most common inflammatory skin condition among the adult and child population that leads to a decrease in the quality of life of patients. Currently there is no curative treatment for the pathology; however, new therapeutic options are being sought for a safe and effective treatment. In the emergence of drugs to treat AD is crisaborole, a novel non-steroidal anti-inflammatory drug, supported by clinical studies and approved by regulatory entities under traditional pharmaceuticalforms that have limitations in dermal administration. Due to the absence in the pharmaceutical market of systems that improve the penetration, absorption and bioavailability of the active ingredient, in the present work it was proposed to develop a crisaborole nanoemulsion. The solubility of the active principle in oils, surfactants andco-surfactants was evaluated; with the mixture of the excipients, an emulsification area was obtained, where the drug was incorporated. The formulation characterized at pH 5 is skin-friendly, has 100nm droplets, is stable at room temperature, and has a sustained release profile.